Indications And Dose
Urinary frequency | Urinary incontinence | Dysuria | Urinary urgency | Bladder spasm due to catheterisation, cytoscopy, or surgery ▶BY MOUTH ▶Adult: 200 mg 3 times a day
PDF page 843
Loading InternPractice…
Drug reference
Urinary frequency | Urinary incontinence | Dysuria | Urinary urgency | Bladder spasm due to catheterisation, cytoscopy, or surgery ▶BY MOUTH ▶Adult: 200 mg 3 times a day
PDF page 843
Gastro-intestinal haemorrhage
PDF page 843
The need for continuing therapy for urinary incontinence should be reviewed every 4–6 weeks until symptoms stabilise, and then every 6–12 months.
PDF page 843
→Appendix 1: flavoxate
PDF page 843
Diarrhoea. dysphagia. eosinophilia. fatigue. hyperpyrexia. hypersensitivity. leucopenia. nervousness. vertigo
PDF page 843
Manufacturer advises avoid unless no safer alternative.
PDF page 843
Manufacturer advises caution—no information available.
PDF page 843
There can be variation in the licensing of different medicines containing the same drug. Forms available from special-order manufacturers include: oral suspension, oral solution Tablet CAUTIONARY AND ADVISORY LABELS 3 ▶Urispas (Recordati Pharmaceuticals Ltd) Flavoxate hydrochloride 200 mg Urispas 200 tablets | 90 tablet P £11.67 DT = £11.67 eiiii F 820
PDF page 843
200 mg 3 times a day
First-line fragment. Read the complete Indications and Dose section above.
PDF page 843